Lung cancer represents 12.9% of all new cancer cases and is the main cause of cancer death in western countries. Only 18% of all lung cancer patients are alive 5 years after diagnosis. However, in recent years, new immunotherapies and other targeted therapies have been developed and approved by the Federal Drug administration (FDA), improving the survival of lung cancer patients.
The National Comprehensive Cancer Network (NCCN) recommends screening of lung cancer patients at diagnosis to define targetable alterations such as EGFR, HER2, and BRAF mutations, ALK, RET, and ROS1 rearrangements, MET genetic alterations, NTRK gene fusions and PD1 expression.
Besides genotyping at diagnosis, Altum test offers monitoring of such alterations after therapy or surgery, by analyzing individual patient cancer-specific alterations in liquid biopsy (peripheral blood) samples. This test of MRD-like measurement assesses treatment response and identifies subsidiary patients who need systematic chemotherapy treatment after surgery in pulmonary resection, monitors remission status and detects early relapse.